Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Citracal Quantified Calcium Absorption Superiority Claims Unproven – NAD

This article was originally published in The Tan Sheet

Executive Summary

Quantified claims that Mission Pharmacal's Citracal calcium supplement is better absorbed than calcium carbonate are not supported by the submitted clinical trials and should be discontinued, NAD concludes in an upcoming NAD Case Reports

You may also be interested in...



Caltrate Absorption Comparison With Citracal Needs Clarification – NAD

Promotional claims implying the absorption of Wyeth's Caltrate calcium supplement is equivalent to Mission Pharmacal's Citracal should be modified "to more clearly reflect the conditions under which bioequivalence was demonstrated," the National Advertising Division concludes following a recent inquiry

Caltrate Absorption Comparison With Citracal Needs Clarification – NAD

Promotional claims implying the absorption of Wyeth's Caltrate calcium supplement is equivalent to Mission Pharmacal's Citracal should be modified "to more clearly reflect the conditions under which bioequivalence was demonstrated," the National Advertising Division concludes following a recent inquiry

Caltrate Absorption Comparison With Citracal Needs Clarification – NAD

Promotional claims implying the absorption of Wyeth's Caltrate calcium supplement is equivalent to Mission Pharmacal's Citracal should be modified "to more clearly reflect the conditions under which bioequivalence was demonstrated," the National Advertising Division concludes following a recent inquiry

Related Content

Topics

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel